公开(公告)号：US20220193136A1

公开(公告)日：2022-06-23

申请号：US17569107

申请日：2022-01-05

申请人： The Regents of the University of California ,  Seattle Children's Hospital DBA Seattle Children's Research Institute

发明人： Yvonne Y. CHEN ,  Eugenia ZAH ,  Michael C. JENSEN

IPC分类号： A61K35/17 ,  C07K16/46 ,  C12N5/0783 ,  C07K16/28 ,  C07K14/725 ,  C07K14/705

摘要： A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.

公开(公告)号：US20210145880A1

公开(公告)日：2021-05-20

申请号：US17028701

申请日：2020-09-22

申请人： The Regents of the University of California ,  Seattle Children's Hospital DBA Seattle Children's Research Institute

发明人： Yvonne Y. CHEN ,  Eugenia ZAH ,  Michael C. JENSEN

IPC分类号： A61K35/17 ,  C07K16/46 ,  C12N5/0783 ,  C07K16/28 ,  C07K14/725 ,  C07K14/705

摘要： A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.

公开(公告)号：US20170368098A1

公开(公告)日：2017-12-28

申请号：US15535972

申请日：2015-12-14

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  SEATTLE CHILDREN'S HOSPITAL DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE

发明人： Yvonne Y. CHEN ,  Eugenia ZAH ,  Michael C. JENSEN

IPC分类号： A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  C07K16/46 ,  C07K14/705 ,  A61K39/00 ,  A61K38/00

CPC分类号： A61K35/17 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70596 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/46 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/40 ,  C12N5/0636 ,  C12N2510/00

摘要： A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.

公开(公告)号：US20210324360A1

公开(公告)日：2021-10-21

申请号：US17357704

申请日：2021-06-24

申请人： The Regents of the University of California

发明人： Yvonne Y. CHEN ,  Patrick HO

IPC分类号： C12N9/64 ,  A61K35/17 ,  C12N15/85 ,  C07K14/47 ,  A61K38/48 ,  C07K16/40 ,  C12N5/0783

摘要： Compositions and methods are provided for the cell-mediated targeted killing of diseased cells based on the presence of an intracellular antigen, rather than a surface-bound marker. The targeting cells are modified to express a cytotoxic protein that is delivered into a targeted cell, and after delivery is selectively activated by the presence of a cytoplasmic protein of interest. In one embodiment of the invention, the cytotoxic molecule is a Granzyme B (GrB) polypeptide. In the compositions of the invention, GrB is modified to render its cytotoxic enzymatic functions inactive, until the presence of an intracellular antigen unlocks the GrB molecule to enable enzymatic activities.

公开(公告)号：US20170362582A1

公开(公告)日：2017-12-21

申请号：US15536009

申请日：2015-12-14

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： Yvonne Y. CHEN ,  Patrick HO

IPC分类号： C12N9/64 ,  C07K16/40 ,  C12N5/0783 ,  A61K35/17 ,  A61K38/48 ,  C07K14/47

CPC分类号： C12N9/6467 ,  A61K35/17 ,  A61K38/482 ,  C07K14/47 ,  C07K14/4702 ,  C07K16/40 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/95 ,  C12N5/0636 ,  C12N15/85 ,  C12N2510/00 ,  C12Y304/21079

摘要： Compositions and methods are provided for the cell-mediated targeted killing of diseased cells based on the presence of an intracellular antigen, rather than a surface-bound marker. The targeting cells are modified to express a cytotoxic protein that is delivered into a targeted cell, and after delivery is selectively activated by the presence of a cytoplasmic protein of interest. In one embodiment of the invention, the cytotoxic molecule is a Granzyme B (GrB) polypeptide. In the compositions of the invention, GrB is modified to render its cytotoxic enzymatic functions inactive, until the presence of an intracellular antigen unlocks the GrB molecule to enable enzymatic activities.